

Clinical trials of angiotensin-receptor blockers for patients at high risk for cardiovascular events in all type of patients

TrialResults-center www.trialresultscenter.org

1 angiotensin receptor blocker

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|---|
| candesartan vs placebo | | | |
| SCOPE , 2003 n=2477/2460 follow-up: 3.7 y (mean) | candesartan, 816 mg once daily (target 160/90) versus placebo | patients aged 70-89 years, with systolic blood pressure 160-179 mmHg, and/or diastolic blood pressure 90-99 mmHg, and a Mini Mental State Examination (MMSE) test score >24 | Parallel groups double-blind 15 countries |
| losartan vs placebo | | | |
| RENAAL , 2001 n=751/762 follow-up: 3.4 years | Losartan 50 to 100 mg once daily versus placebo | patients with type 2 diabetes and nephropathy | Parallel groups double-blind |
| telmisartan vs placebo | | | |
| TRANSCEND , 2008 [NCT00153101] n=2954/2972 follow-up: median 56 months (IQR 51-64) | telmisartan 80 mg/day versus placebo | high-risk patients intolerant to angiotensin-converting enzyme inhibitors | Parallel groups double blind 40 countries |
| PROPHESSE , 2008 [NCT00153062] n=10146/10186 follow-up: 2.5 y | telmisartan 80 mg daily versus placebo | patients who recently had an ischemic stroke | Factorial plan double blind 35 countries |
| valsartan vs amlodipine | | | |
| VALUE , 2004 [NCT00129233] n=7649/7596 follow-up: 4.2 y (mean) | valsartan based regimen versus amlodipine based regimen | patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events | Parallel groups Double blind 31 countries |
| losartan vs atenolol | | | |
| LIFE , 2002 n=4605/4588 follow-up: 4.8 y (mean) | losartan versus atenolol | patients aged 55-80 years, with previously treated or untreated hypertension (sitting blood pressure 160/200/95/115 mm Hg) and ECG signs of LVH. | Parallel groups Double blind USA, Europe |
| telmisartan vs ramipril | | | |
| ONTARGET (telmisartan alone) , 2008 [NCT00153101] n=8542/8576 follow-up: 4.7y | telmisartan 80mg daily versus ramipril 10 mg daily | patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage | Parallel groups double blind 40 countries |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|---|
| telmisartan + ramipril vs ramipril | | | |
| ONTARGET (association vs ramipril), 2008 [NCT00153101] n=8502/8576 follow-up: 4.7y | telmisartan 80mg + ramipril 10mg daily versus ramipril 10 mg daily | patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage | Parallel groups double blind 40 countries |
| telmisartan + ramipril vs telmisartan | | | |
| ONTARGET (association vs telmisartan), 2008 [NCT00153101] n=8502/8542 follow-up: 4.7y | telmisartan 80mg + ramipril 10mg daily versus telmisartan 80 mg daily | patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage | Parallel groups double blind 40 countries |

References

SCOPE, 2003:

Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. *Neurology* 2008;70:1858-66 [[18458219](#)] [10.1212/01.wnl.0000311447.85948.78](#)

Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens* 2003;21:875-86 [[12714861](#)] [10.1097/01.hjh.0000059028.82022.89](#)

RENAAL, 2001:

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;345:861-9 [[11565518](#)]

TRANSCEND, 2008:

PROPHESSE, 2008:

Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, — *N Engl J Med* 2008;359:1225-37 [[18753639](#)] [10.1056/NEJMoa0804593](#)

VALUE, 2004:

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet* 2004 Jun 19;363:2022-31 [[15207952](#)]

LIFE, 2002:

Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002 Mar 23;359:995-1003 [[11937178](#)]

ONTARGET (telmisartan alone), 2008:

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med* 2008 Apr 10;358:1547-59 [[18378520](#)] [10.1056/NEJMoa0801317](#)

Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfeld J, Teo K, Yusuf S Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. *Circulation* 2009;120:1380-9 [[19770395](#)]

ONTARGET (association vs ramipril), 2008:

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10;358:1547-59 [[18378520](#)]

ONTARGET (association vs telmisartan), 2008:

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10;358:1547-59 [[18378520](#)]

2 endopeptidase inhibitors

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---|
| LCZ696 vs placebo | | | |
| Ruilope , 2010 n=NA follow-up: 8 weeks | LCZ696 for 8 weeks versus placebo | patients with mild to moderate hypertension | Parallel groups double blind 18 countries |

References

Ruilope, 2010:

Ruilope LM, Dukat A, Bhm M, Lacourcire Y, Gong J, Lefkowitz MP Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010 Mar 15;: [[20236700](#)] [10.1016/S0140-6736\(09\)61966-8](#)

3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.